To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.
Age 18 years or older.
Diagnosis of CLL/SLL per 2018 iwCLL criteria (See Appendix 1).
Participants with previously treated CLL requiring therapy based on 2018 iwCLL criteria.
The participant is able to take oral medications.
Participants who experienced progression of disease according to 2018 iwCLL criteria while on venetoclax will be excluded.
Patient with prior history of Richter's syndrome or current Richter's Syndrome.
Participants with known hypersensitivity to any of the excipients of pirtobrutinib, venetoclax,obinutuzumab or to any intended study medications.
Known or suspected history of central nervous system (CNS) involvement by CLL/SLL.
M.D. Anderson Cancer Center
Lead sponsor
Eli Lilly and Company
Collaborator